NFE2L2 and non-small cell squamous lung carcinoma: Sapanisertib continues in limited clinical development, primarily focusing on patients with squamous non-small cell lung cancer with KEAP1/NRF2 (NFE2L2) mutations (Calithera Biosciences, 2021; Paik et al., 2023).